AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

F&P Healthcare drop leads NZX lower, rural stocks show strength
Markets Market Close

F&P Healthcare drop leads NZX lower, rural stocks show strength

Rural services group PGG Wrightson rose 14c or 6.9% to $2.17. 

Jamie Gray 11 Jul 2025
Tait won’t up its offer for Vital ‘under any circumstances’
Markets

Tait won’t up its offer for Vital ‘under any circumstances’

Suitor says offer is ‘at the maximum’ of its assessment of target’s value.

Rebecca Howard 11 Jul 2025
Lights, camera, cashflow: Forsyth Barr upgrades Vista
Markets

Lights, camera, cashflow: Forsyth Barr upgrades Vista

Analysts also lifted their 12-month target price by 5% to $4.30.

Rebecca Howard 11 Jul 2025
Vital holder slams takeover valuation report
Markets

Vital holder slams takeover valuation report

Matt Goodson says the Grant Samuel report was ‘particularly uninformative’. 

Gregor Thompson 11 Jul 2025